PureTech Health PLC (PRTC)
Official siteBIOTECHNOLOGY
Last updated: Nov 06, 2026 at 4:00 PM ET
PureTech Health PLC (PRTC) Financials: Revenue, Profit and Cash Flow
PureTech Health reported revenue of $4.66M for the fiscal year ended Dec 31, 2025, down 3.5% from the year before. That year, net income was -$109.74M with a net margin of -2355.4%, operating cash flow was -$85.33M and free cash flow was -$85.34M. The quarter ended Mar 31, 2026 had revenue of $2.80M and net income of -$64.89M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $4.43M, a compound annual rate of 0.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.66M | -3.5% | 100.0% | -2114.7% | -2355.4% |
| Dec 2024 | $4.83M | +45.0% | 26.0% | -2818.9% | 1108.3% |
| Dec 2023 | $3.33M | +59.3% | -48.1% | -4390.4% | -1972.9% |
| Dec 2022 | $2.09M | -79.1% | -6546.2% | -9464.4% | -2409.3% |
| Dec 2021 | $9.98M | +19.6% | -1007.0% | -1506.0% | -606.9% |
| Dec 2020 | $8.34M | -4.0% | 100.0% | -1433.1% | 71.8% |
| Dec 2019 | $8.69M | -46.9% | -888.1% | -1558.5% | 4847.4% |
| Dec 2018 | $16.37M | +2418.6% | -372.8% | -635.4% | -266.7% |
| Dec 2017 | $650.00K | -85.3% | -10828.5% | -17756.9% | 4749.1% |
| Dec 2016 | $4.43M | N/A | 64.6% | -1668.4% | -1101.2% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Mar 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.66M | $4.83M | $3.33M | $2.09M | $9.98M | $8.34M | $8.69M | $16.37M | $650.00K | $4.43M |
| Cost of revenue | $0 | $3.57M | $4.93M | $152.43M | $110.47M | $0 | $85.85M | $77.40M | $71.03M | $1.57M |
| Gross profit | $4.66M | $1.26M | -$1.60M | -$136.81M | -$100.49M | $8.34M | -$77.16M | -$61.03M | -$70.39M | $2.86M |
| Research and development | $45.74M | $54.28M | $96.23M | $116.11M | $81.52M | $61.19M | $65.17M | $57.29M | $71.67M | $41.20M |
| Operating income | -$98.53M | -$136.09M | -$146.20M | -$197.81M | -$150.28M | -$119.53M | -$135.40M | -$104.02M | -$115.42M | -$73.93M |
| Net income | -$109.74M | $53.51M | -$65.70M | -$50.35M | -$60.56M | $5.99M | $421.14M | -$43.65M | $30.87M | -$48.79M |
| EBITDA | -$61.80M | $37.38M | -$11.63M | -$188.91M | $26.70M | $62.69M | $487.78M | -$65.27M | -$40.79M | N/A |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.80M | $2.80M | $1.85M | $4.03M | $4.03M | $288.00K | $178.57K | $178.57K | $90.00K | $3.15M | $9.01M | $9.01M |
| Gross profit | $1.15M | $1.15M | -$23.05M | $42.95M | $42.95M | -$38.64M | -$1.68M | -$1.68M | -$21.45M | $89.00K | -$24.92M | -$24.92M |
| Operating income | -$50.40M | -$50.40M | -$47.93M | -$69.70M | -$69.70M | -$66.40M | -$69.48M | -$69.48M | -$35.02M | -$76.16M | -$101.34M | -$101.34M |
| Net income | -$64.89M | -$64.89M | -$44.60M | $95.28M | $95.28M | -$41.77M | -$40.37M | -$40.37M | -$20.35M | -$25.00M | -$23.09M | -$23.09M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $4.92M by $249.15M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $534.71M | $602.63M | $693.97M | $702.65M | $946.01M | $989.99M | $941.18M | $441.76M | $339.85M | $298.75M |
| Current assets | $305.02M | $386.26M | $347.20M | $386.19M | $501.81M | $414.35M | $168.84M | $259.79M | $198.11M | $288.15M |
| Cash and equivalents | $254.07M | $280.64M | $191.08M | $149.87M | $465.71M | $403.88M | $132.36M | $117.05M | $72.65M | $62.96M |
| Total liabilities | $229.03M | $194.70M | $235.74M | $155.06M | $361.86M | $336.45M | $290.78M | $274.79M | $275.85M | $206.34M |
| Short-term debt | $4.92M | $4.11M | $3.70M | $7.50M | $5.50M | $26.45M | $1.46M | $12.01M | -$121.56M | -$81.43M |
| Long-term debt | $0 | $0 | $0 | $10.24M | $14.26M | $14.82M | $0 | $357.00K | N/A | N/A |
| Shareholder equity | $312.07M | $414.71M | $464.07M | $542.22M | $593.51M | $669.75M | $668.04M | $275.51M | $214.30M | $177.67M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $534.71M | $534.71M | $553.24M | $602.63M | $602.63M | $579.95M | $693.97M | $693.97M | $693.97M | $693.55M | $702.65M | $702.65M |
| Total liabilities | $229.03M | $229.03M | $184.22M | $194.70M | $194.70M | $273.74M | $235.74M | $235.74M | $235.74M | $184.66M | $155.06M | $155.06M |
| Cash and equivalents | $254.07M | $254.07M | $262.25M | $280.64M | $280.64M | $308.48M | $191.08M | $191.08M | $191.08M | $350.51M | $149.87M | $149.87M |
| Shareholder equity | $312.07M | $312.07M | $375.98M | $414.71M | $414.71M | $315.87M | $464.07M | $464.07M | $464.07M | $513.67M | $542.22M | $542.22M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$85.33M | -$134.37M | -$105.92M | -$178.79M | -$158.27M | -$131.83M | -$98.16M | -$72.80M | -$88.69M | -$58.03M |
| Capital expenditures | $6.01K | $11.00K | $245.00K | $2.18M | $5.66M | $5.42M | $12.54M | $4.49M | $2.17M | $3.68M |
| Free cash flow | -$85.34M | -$134.38M | -$106.16M | -$180.97M | -$163.94M | -$137.25M | -$110.69M | -$77.29M | -$90.86M | -$61.71M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $112.00K | $8.00K | $91.00K | N/A |
| Share repurchases | $2.06M | $107.56M | $19.65M | $26.49M | $13.33M | $0 | $1.28M | $35.00K | N/A | N/A |
| Investing cash flow | $63.44M | $240.89M | $68.99M | -$107.22M | $197.38M | $364.48M | $63.66M | -$39.65M | $83.68M | -$43.23M |
| Financing cash flow | -$6.34M | -$16.96M | $78.14M | -$29.83M | $22.73M | $38.87M | $49.91M | $156.89M | $14.70M | $29.49M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.47M | -$38.47M | -$46.34M | -$53.00M | -$54.35M | -$80.01M | -$39.94M | -$39.94M | -$20.39M | -$65.13M | -$100.30M | -$100.30M |
| Capital expenditures | $5.98K | $5.98K | $3 | $11.00K | $11.00K | $4 | $173.05K | $173.05K | $0 | $70.00K | $635.53K | $635.53K |
| Free cash flow | -$38.48M | -$38.48M | -$46.34M | -$53.01M | -$54.37M | -$80.01M | -$40.12M | -$40.12M | -$20.39M | -$65.20M | -$100.93M | -$100.93M |
Frequently Asked Questions About PRTC
What is PureTech Health's annual revenue?
PureTech Health reported revenue of $4.66M for the fiscal year ended Dec 31, 2025.
How fast is PureTech Health's revenue growing?
Revenue was down 3.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 30.6%.
Is PureTech Health profitable?
No. PureTech Health reported net income of -$109.74M for the fiscal year ended Dec 31, 2025, with a net margin of -2355.4%.
How much free cash flow does PRTC generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$85.33M minus capital expenditures of $6.01K produced free cash flow of -$85.34M.
How much debt does PureTech Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $4.92M and cash and equivalents of $254.07M.
PRTC pages: Overview, Financials